Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 31-40 of 40 (Search time: 0.002 seconds).
previous
1
2
3
4
next
Item hits:
Preview
Issue Date
Title
Author(s)
2005
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Dewar, A.
;
Cambareri, A.
;
Zannettino, A.
;
Boog, B.
;
Doherty, K.
;
Hughes, T.
;
Lyons, A.
2006
OCT-1-mediated influx is a key determinant of the intraceflular uptake of imatinib but not nilotinib, (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Zannettino, A.
;
Cambareri, A.
;
Quinn, S.
;
Manley, P.
;
Hughes, T.
2009
Chronic myeloid leukemia: An update of concepts and management recommendations of European LeukemiaNet
Baccarani, M.
;
Cortes, J.
;
Pane, F.
;
Niederwieser, D.
;
Saglio, G.
;
Apperley, J.
;
Cervantes, F.
;
Deininger, M.
;
Gratwohl, A.
;
Guilhot, F.
;
Hochhaus, A.
;
Horowitz, M.
;
Hughes, T.
;
Kantarjian, H.
;
Larson, R.
;
Radich, J.
;
Simonsson, B.
;
Silver, R.
;
Goldman, J.
;
Hehlmann, R.
2009
Dasatinib in the Treatment of Chronic Myeloid Leukemia in Accelerated Phase After Imatinib Failure: The START A Trial
Apperley, J.
;
Cortes, J.
;
Kim, D.
;
Roy, L.
;
Roboz, G.
;
Rosti, G.
;
Bullorsky, E.
;
Abruzzese, E.
;
Hochhaus, A.
;
Heim, D.
;
De Souza, C.
;
Larson, R.
;
Lipton, J.
;
Khoury, J.
;
Kim, H.
;
Sillaber, C.
;
Hughes, T.
;
Erben, P.
;
Tornout, J.
;
Stone, R.
2007
Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity
White, D.
;
Saunders, V.
;
Dang, P.
;
Engler, J.
;
Venables, A.
;
Zrim, S.
;
Zannettino, A.
;
Lynch, K.
;
Manley, P.
;
Hughes, T.
2007
Imatinib increases the intracellular concentration of nilotinib which may explain the observed synergy between these drugs
White, D.
;
Saunders, V.
;
Quinn, S.
;
Manley, P.
;
Hughes, T.
2003
Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis
Branford, S.
;
Rudzki, Z.
;
Walsh, S.
;
Parkinson, I.
;
Grigg, A.
;
Szer, J.
;
Taylor, K.
;
Hermann, R.
;
Seymour, J.
;
Arthur, C.
;
Joske, D.
;
Lynch, K.
;
Hughes, T.
2008
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications
Hiwase, D.
;
Saunders, V.
;
Hewett, D.
;
Frede, A.
;
Zrim, S.
;
Dang, P.
;
Eadie, L.
;
To, L.
;
Vaz de Melo, J.
;
Kumar, S.
;
Hughes, T.
;
White, D.
2008
Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease
Ross, D.
;
Watkins, D.
;
Hughes, T.
;
Branford, S.
2005
Inhibition of c-fms by imatinib - Expanding the spectrum of treatment
Dewar, A.
;
Zannettino, A.
;
Hughes, T.
;
Lyons, A.
Discover
Author
13
Branford, S.
12
Hochhaus, A.
8
White, D.
6
Cortes, J.
6
Goldman, J.
6
Radich, J.
5
Grigg, A.
5
Rudzki, Z.
5
To, L.
4
Apperley, J.
.
next >
Subject
27
Leukemia, Myelogenous, Chronic, B...
25
Pyrimidines
24
Benzamides
24
Imatinib Mesylate
24
Piperazines
20
Fusion Proteins, bcr-abl
16
Male
14
Adult
14
Antineoplastic Agents
14
Female
.
next >
Date issued
8
2009
6
2008
2
2007
4
2006
3
2005
2
2004
7
2003
4
2002
1
2001
3
2000
.
next >